Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon to Launch 3 Pivotal Trials for Napabucasin in FY2015, Postpone BBI503 Program
December 10, 2015
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Mitsubishi Chemical Holdings to Invest in New Production Facilities for Drugs and Vaccines
December 10, 2015
- Stephen Hitchcock Tapped as Head of Pharma Research at Takeda
December 9, 2015
- Takeda Ties Up with US Biotech Cour on Immune Modulating Therapies
December 9, 2015
- Ethical Drug Sales Zoom 10.7% in October: Crecon Report
December 9, 2015
- Mega Mergers Not the Best Way to Get Drug Discovery Prowess: Astellas President
December 9, 2015
- Sovaldi Top-Prescribed Drug at Japanese Acute Hospitals in July-Sept.
December 8, 2015
- Belsomra Most Promoted Drug for GPs for 4 Months Running: Anterio
December 8, 2015
- Otsuka Seeks Japan Approval of Abilify for Juvenile Autism-Linked Excitability
December 8, 2015
- MM Treatment Ixazomib Extends PFS in PIII: Takeda
December 8, 2015
- Nothing Decided for Japan Market over Pfizer’s Allergan Acquisition: Umeda
December 7, 2015
- Global PII for Pediatric X-Linked Hypophosphatemia Yields Positive Data: Kyowa Kirin
December 7, 2015
- Kyowa Kirin Kicks Off Global PIII for Adult X-Linked Hypophosphatemia
December 7, 2015
- Unusualness of Hep C Market Not Being Understood, Gilead COO Says on Possible Sovaldi Re-Pricing
December 4, 2015
- Nichi-Iko Sells Off Shares Held in South Korean Firm
December 3, 2015
- GSK’s Drug Supplies Disrupted by Manufacturing Woes Overseas
December 2, 2015
- Japan NDA for IBS-C Drug Linaclotide Planned in 2016: Astellas
December 2, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Daiichi Sankyo to Shutter German Biotech Unit amid R&D Cost-Cut Drive
December 2, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…